The focus of this project is on ependymoma, a pediatric brain tumor with various subtypes. The drivers of each of these subtypes and drug targets for treatments in these types have not been identified. Changes in the genome, called genetic alterations, are known to have pivotal roles in the development and progression of cancers. One form of gene alteration that takes place in cancers are transcript isoforms. The goal of this project is to identify transcript isoforms that are only present in specific subtypes of ependymoma. This insight could lead to better treatment options and a better outcome for patients. To complete this important work, researchers will access the ependymoma data represented in the Pediatric Brain Tumor Atlas.
What are the goals of this project?
Researchers will perform analyses to better understand different subtypes of ependymoma and the treatment they require.
What is the impact of this project?
This project will identify genetic alterations associated with various ependymoma subtypes in an effort to identify targets for new therapeutics.
Why is the CBTN request important to this project?
The Pediatric Brain Tumor Atlas provides researchers with rare data across ependymoma subtypes.
The Children's Brain Tumor Network contributed to this project by providing access to the Pediatric Brain Tumor Atlas.
The analysis will be done by Anke Heit-Mondrzyk, Marcel Kool and Natalie Jäger (Hopp-Children’s Cancer Center, Heidelberg, Germany).
Ependymomas arise from ependymal cells that line the ventricles and passageways in the brain and the center of the spinal cord. Ependymal cells produce cerebrospinal fluid (CSF). These tumors are classified as supratentorial or infratentorial. In children, most ependymomas are infratentorial tumors